MX2024001645A - Metodo para el tratamiento de las enfermedades virales veterinarias. - Google Patents

Metodo para el tratamiento de las enfermedades virales veterinarias.

Info

Publication number
MX2024001645A
MX2024001645A MX2024001645A MX2024001645A MX2024001645A MX 2024001645 A MX2024001645 A MX 2024001645A MX 2024001645 A MX2024001645 A MX 2024001645A MX 2024001645 A MX2024001645 A MX 2024001645A MX 2024001645 A MX2024001645 A MX 2024001645A
Authority
MX
Mexico
Prior art keywords
disease
feline
viral diseases
viral
treating
Prior art date
Application number
MX2024001645A
Other languages
English (en)
Spanish (es)
Inventor
Ralf Warrass
Joachim Ullrich
Edward Murray
Basav Hangalapura Nagaraj
Willem Huisman
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2024001645A publication Critical patent/MX2024001645A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024001645A 2021-08-06 2022-08-05 Metodo para el tratamiento de las enfermedades virales veterinarias. MX2024001645A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21190172 2021-08-06
EP22185716 2022-07-19
PCT/EP2022/072074 WO2023012329A1 (en) 2021-08-06 2022-08-05 Method of treating veterinary viral diseases

Publications (1)

Publication Number Publication Date
MX2024001645A true MX2024001645A (es) 2024-02-27

Family

ID=83151800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001645A MX2024001645A (es) 2021-08-06 2022-08-05 Metodo para el tratamiento de las enfermedades virales veterinarias.

Country Status (8)

Country Link
US (1) US20240342204A1 (https=)
EP (1) EP4380578A1 (https=)
JP (1) JP2024528237A (https=)
AU (1) AU2022323465A1 (https=)
BR (1) BR112024002195A2 (https=)
CA (1) CA3226836A1 (https=)
MX (1) MX2024001645A (https=)
WO (1) WO2023012329A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300412A (en) 2020-08-24 2023-04-01 Gilead Sciences Inc Phospholipid compounds and their uses
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5030587B2 (ja) 2003-06-26 2012-09-19 バイオトロン・リミテッド 抗ウイルスアシルグアニジン化合物および方法
NZ615939A (en) 2011-05-10 2015-04-24 Aratana Therapeutics Nv Compounds for use in the treatment of feline retroviral infections
GB201203180D0 (en) 2012-02-24 2012-04-11 Okapi Sciences Nv Compounds for treating parvovirus infection
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ N4-ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
KR20200140274A (ko) 2018-03-07 2020-12-15 에모리 유니버시티 4'-할로겐 함유 뉴클레오티드 및 뉴클레오시드 치료 조성물 및 이와 관련된 용도

Also Published As

Publication number Publication date
CA3226836A1 (en) 2023-02-09
WO2023012329A1 (en) 2023-02-09
JP2024528237A (ja) 2024-07-26
US20240342204A1 (en) 2024-10-17
AU2022323465A1 (en) 2024-02-01
EP4380578A1 (en) 2024-06-12
BR112024002195A2 (pt) 2024-04-30

Similar Documents

Publication Publication Date Title
MX2024001645A (es) Metodo para el tratamiento de las enfermedades virales veterinarias.
De Clercq et al. (S)-9-(2, 3-Dihydroxypropyl) adenine: an aliphatic nucleoside analog with broad-spectrum antiviral activity
FI87783C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 2',3'-dideoxinukleosider
JP2019519553A5 (https=)
KR890700035A (ko) 개량된 인터페론 요법
BR0316397A (pt) Tiouréias aril substituìdas e compostos relacionados como inibidores de replicação viral
RU2411039C2 (ru) Иммунокорригирующее средство для лечения заболеваний вирусной этиологии
BRPI0506705A (pt) composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos
JP2023520323A5 (https=)
CA2452075A1 (en) Sustained release delivery system
HRP20241435T1 (hr) Nova upotreba agonista angiotenzinskog ii receptora tipa 2
BR112022019198A2 (pt) Composição farmacêutica para a prevenção ou tratamento de infecções por vírus de ácido ribonucleico epidêmico, e, uso de uma quantidade terapeuticamente eficaz de pironaridina ou um sal farmaceuticamente aceitável da mesma e artemisinina ou um derivado da mesma
Sabroe et al. Treatment of adenoviral pneumonitis with intravenous ribavirin and immunoglobulin.
CN112439058A (zh) 基于外泌体为载体的重组新型冠状病毒纳米疫苗方法
WO2021175250A1 (en) Compounds and methods for treating diseases and/or conditions caused by coronavirus
WO2008036747A2 (en) Composition and method for immunomodulation
JP2024528237A5 (https=)
HRP20240949T1 (hr) Hibridni interferoni za liječenje virusnih infekcija
FR2694693B1 (fr) Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH.
TW528599B (en) Stimulation of host defense mechanisms against viral challenges
Loveridge et al. CrOCOClile Immobilization and Anaesthesia
RU2554495C2 (ru) Цитокинсодержащее лекарственное средство, обладающее противовирусным, противомикробным, иммуномодулирующим и противовоспалительным действием для профилактики и лечения инфекционных заболеваний
RU2024105614A (ru) Способ лечения вирусных ветеринарных заболеваний
CA1329122C (en) Prevention of bovine respiratory disease complex in cattle by administration of interferon
MX2022011539A (es) Metodo de produccion de una composicion de suero para la prevencion o el tratamiento de enfermedades infecciosas relacionadas con las mucosas en mamiferos jovenes, composicion de suero producida de este modo y uso de la misma.